A randomized phase II trial of SRL172 (Mycobacterium vaccae) ± low-dose interleukin-2 in the treatment of metastatic malignant melanoma

Melanoma Research

Volumn 13, Issue 4, 2003, Pages 389-393

  Nicholson, S ^a,b   Guile, K ^a   John, J ^a   Clarke, I A ^a   Diffley, J ^a   Donnellan, P ^a   Michael, A ^a   Szlosarek, P ^a   Dalgleish, A G ^a  

^a ST GEORGE'S UNIVERSITY OF LONDON   (United Kingdom)

^b ST BARTHOLOMEW S HOSPITAL   (United Kingdom)

Author keywords

Clinical trial; Immunotherapy; Melanoma

Indexed keywords

INTERLEUKIN 2; SRL 172; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CANCER IMMUNOTHERAPY; CANCER REGRESSION; CLINICAL TRIAL; HUMAN; IMMUNOTHERAPY; LOW DRUG DOSE; MELANOMA; METASTASIS; MYCOBACTERIUM VACCAE; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; REMISSION; SKIN TUMOR; TREATMENT OUTCOME;

ADJUVANTS, IMMUNOLOGIC; ADULT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BACTERIAL VACCINES; DISEASE-FREE SURVIVAL; HUMANS; IMMUNOTHERAPY; INTERLEUKIN-2; MELANOMA; MIDDLE AGED; MYCOBACTERIUM; SKIN NEOPLASMS; TREATMENT OUTCOME;

EID: 0041365767     PISSN: 09608931     EISSN: None     Source Type: Journal    
DOI: 10.1097/00008390-200308000-00008     Document Type: Article

References (17)

1. Khayat D, Coeffic D, Antoine E-C. Overview of medical treatment of metastatic malignant melanoma. In: Perry M, editor. ASCO (Educational Book) 2000. American Society of Clinical Oncology, Alexandria, VA, New Orleans, LA: 2000, pp. 413-427.
2. Grange J, Stanford J, Rook G. TB and cancer: parallels in host responses and therapeutic approaches. Lancet 1995; 345:13 450-13 452.
3. Skinner M, Yuan S, Prestidge R, Chuk D, Watson J, Tan P. Immunization with heat-killed Mycobacterium vaccae stimulates CDS+ cytotoxic T cells specific for macrophages infected with Mycobacterium tuberculosis. Infect Immun 1997; 65 (11):4525-4530.
4. Tian X, Groves M. Formulation and biological activity of antineoplastic proteoglycans derived from Mycobacterium vaccae in chitosan nanoparticles. J Pharmacy Pharmacol 1999; 51 (2):151-157.
5. Clerici B, Enrico E, Shearer G. Tumour enhancement phenomenon: reinterpretation from a Th1/Th2 perspective. J Natl Cancer Inst 1996; 88:461-462.
6. Wang C, Rook G. Inhibition of an established allergic response to ovalbumin in BALB/c mice by killed Mycobacterium vaccae. Immunology 1998; 93 (3):307-313.
7. Maraveyas A, Baban B, Kennard D, et al. Possible improved survival of patients with stage IV AJCC melanoma receiving SRL172 immunotherapy: correlation with induction of increased levels of intracellular interleukin-2 in peripheral blood lymphocytes. Ann Oncol 1999; 10:817-824.
8. Hrouda D, Baban B, Dunsmuir W, Kirby R, Dalgleish A. Immunotherapy of advanced prostate cancer: a phase I/II trial using Mycobacterium vaccae (SRL172). Br J Urol 1998; 82 (4):568-573.
9. O'Brien M, Saini A, Smith I, et al. A randomized phase II study of SRL172 (Mycobacterium vaccae) combined with chemotherapy in patients with advanced inoperable non-small-cell lung cancer and mesothelioma. Br J Cancer 2000; 83 (7):853-857.
10. Sparano J, Fisher R, Sunderland M, et al. Randomized phase III trial of treatment with high-dose interleukin-2 either alone or in combination with interferon alfa-2a in patients with advanced melanoma. J Clin Oncol 1993; 11 (10):1969-1977.
11. Phan G, Attia P, Steinberg S, White D, Rosenberg S. Factors associated with response to high-dose interleukin-2 in patients with metastatic melanoma. J Clin Oncol 2001; 19:3477-3482.
12. Westby M, Marriott J, Guckian M, Cookson S, Hay P, Dalgleish A. Abnormal intracellular IL-2 and interferon-gamma (IFN-γ) production as HIV-1-associated markers of immune dysfunction. Clin Exp Immunol 1998; 111 (2):257-263.
13. Rosenberg S, Yang J, Schwartzentruber D, et al. Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma. Nature Med 1998; 4 (3):321-327.
14. Morton D, Eilber F, Holmes E, et al. BCG immunotherapy of malignant melanoma: summary of a seven year experience. Ann Surg 1974; 180:635-643.
15. Protti M, Heltai S, Bellone M, Ferrarini M, Manfredi A, Rugarli C. Constitutive expression of the heat shock protein 72 kDa in human melanoma cells. Cancer Lett 1994; 85 (2):211-216.
16. Lazaris A, Theodoropoulos G, Aroni K, Saetta A, Davaris P. Immunohistochemical expression of C-myc oncogene, heat shock protein 70 and HLA-DR molecules in malignant cutaneous melanoma. Virchows Arch 1995; 426 (5):461-467.
17. Skinner M, Prestidge R, Yuan S, Strabala T, Tan P. The ability of heat-killed Mycobacterium vaccae to stimulate a cytotoxic T-cell response to an unrelated protein is associated with a 65 kilodalton heat-shock protein. Immunology 2001; 10 (2):225-233.